



*Optometry and Vision Science*

Author's Accepted Manuscript

**Article Title:** Topical Review: Studies on Management of Myopia Progression from 2019 to 2021

**Authors:** Lanca C, Repka MX, Grzybowski A

**DOI:** 10.1097/OPX.0000000000001947

This manuscript has been accepted by *Optometry and Vision Science*, but has not been copy-edited. This information is subject to change. Final copy-editing and production will correct errors in language usage and text. Figures and tables may be changed and pages will be composed into their final format.

Visit the journal's website (<https://journals.lww.com/optvissci/>) for the final version of this article.

If citing the article, please follow this example:

Lanca C, Repka MX, Grzybowski A. Topical Review: Studies on Management of Myopia Progression from 2019 to 2021. *Optom Vis Sci*: DOI: 10.1097/OPX.0000000000001947.

## REVIEW

### **Topical Review: Studies on Management of Myopia Progression from 2019 to 2021**

Carla Lanca, PhD, Michael X. Repka, MD, MBA, Andrzej Grzybowski, MD, PhD, MBA

Escola Superior de Tecnologia da Saúde de Lisboa (ESTeSL), Instituto Politécnico de Lisboa, Lisboa, Portugal (CL), Comprehensive Health Research Center (CHRC), Escola Nacional de Saúde Pública, Universidade Nova de Lisboa, Lisboa, Portugal (CL), Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland (MXR), Department of Ophthalmology, University of Warmia and Mazury, Olsztyn, Poland (AG), and Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, Poznan, Poland (AG)

Submitted: April 6, 2022; accepted September 2, 2022.

Corresponding author:

Andrzej Grzybowski

ae.grzybowski@gmail.com

## **ABSTRACT**

**Significance.** Myopia is a common eye condition that increases the risk of sight threatening complications. Each additional diopter increases the chance of complications. The purpose of this review is to make an overview of myopia control treatment options for children with myopia progression.

In this non-systematic review, we searched PubMed and Cochrane databases for English-language studies published from 2019 through September 2021. Emphasis was given to selection of randomized controlled trials. Nineteen randomized controlled trials and two retrospective studies were included. Topical atropine and orthokeratology remain the most used treatments, while lenses with novel designs are emerging treatments. Overall myopia progression in the treatment groups for low dose atropine and orthokeratology were lower than the control groups and their efficacy was reported in several randomized controlled trials and confirmed by various systematic reviews and meta-analysis. The findings of myopia progression and axial elongation for the MiSight, defocus incorporated multiple segments spectacle lens, highly aspherical lenslets and diffusion optics technology spectacle lens were comparable. Public health interventions to optimize environmental influences may also be important strategies to control myopia. Optimal choice of management of myopia depends on treatment availability, acceptability to child and parents, and specific patient features such as age, baseline myopia and lifestyle. Eye care providers need to understand the advantages and disadvantages of each therapy to best counsel parents of children with myopia.

Myopia is a common eye condition caused by excessive elongation of the eye, resulting in blurred vision for distance. Approximately 30% of the world population had myopia in 2020. The prevalence is expected to rise to 50% by 2050.<sup>1</sup> Although the risk of complications is higher for high myopia, low and moderate myopia may also develop complications.<sup>2,3</sup> Each additional 1 diopter (D) of myopia increases the risk of complications such as myopic maculopathy (58%), retinal detachment (30%), posterior subcapsular cataract (21%) and open-angle glaucoma (20%).<sup>4</sup> Risk factors for myopia include decreased time spent outdoors, number of years of education, increased time spent on near-work and parental myopia.<sup>5-8</sup> Recent data suggest an increased myopia incidence among children during the COVID-19 pandemic due to a significant decrease in outdoor time and increase in screen time.<sup>9,10</sup> Early-age of myopia onset plays a fundamental role in myopia progression as 50% of children with myopia onset at 7 or 8 years of age develop high myopia in adulthood.<sup>11</sup> Children with spherical equivalent refractive error between -1.5 D and -3 D at 10 years had a 46% risk of developing high myopia in adulthood and treatment to slow the rate of progression is advisable.<sup>12</sup> The purpose of this review is to provide an evidence-based update of therapy options for myopia progression.

## **METHODS**

In this non-systematic review, we searched PubMed and the Cochrane databases for English-language studies published from 2019 through September 2021, for randomized controlled trials, meta-analyses, systematic reviews, and observational studies. We also manually searched the references of selected articles, reviews, meta-analyses, and practice guidelines. Selected articles were mutually agreed upon by the authors. Emphasis was given to selection of randomized

controlled trials. Previous evidence-based reviews/meta-analysis published prior to 2019 are generally available and were not included in this study.<sup>13-16</sup>

## **RESULTS AND DISCUSSION**

Traditional spectacles are the most common and the cheapest option in the treatment of myopia. However, in children at risk of fast myopia progression, other options may be considered such as topical atropine, orthokeratology, contact lenses or multifocal spectacles with novel technology and designs. Treatment combinations such as atropine with orthokeratology or with multifocal contact lenses or spectacles may also be used. Public health interventions, including lifestyle recommendations for optimization of environmental influences are also important strategies to control myopia incidence.

### **Topical Low-dose Atropine**

Atropine is an anti-muscarinic agent and can be used as a monotherapy or as a combination treatment (Table 1). Atropine has been advocated as the first line of treatment in children with lower cost compared with other therapies. The effectiveness and safety of topical atropine were tested in numerous studies over a period of more than 30 years. One of the first randomized controlled trials was conducted in the 1980s and showed that 1% atropine eye drops were effective in the control of myopia progression.<sup>17</sup> The Atropine for Treatment of Myopia Studies (ATOM 1 & 2) are landmark randomized clinical trials that proved the effectiveness of low dose atropine (0.01 %) with a long follow-up of five-years in Singapore, but those studies were limited by the absence of a placebo control group.<sup>18</sup> The principal disadvantages of topical atropine therapy are a reduction of the amplitude of accommodation and photophobia with

higher concentrations (0.1% and higher).<sup>19</sup> Nevertheless, the results from the Low-Concentration Atropine for Myopia Progression (LAMP) study (3-year randomized controlled trial) in Chinese children showed that low concentrations side effects and mild and well tolerated.<sup>20-22</sup> The results from the LAMP study showed that 0.05% atropine conferred the best efficacy compared with 0.025% and 0.01% concentrations.<sup>20-22</sup> Increases in myopia in treated groups vs. washout groups for the 0.05%, 0.025%, and 0.01% concentrations were  $-0.28 \pm 0.42$  D (vs  $-0.68 \pm 0.49$  D),  $-0.35 \pm 0.37$  D (vs  $-0.57 \pm 0.38$  D) and  $-0.38 \pm 0.49$  D (vs  $-0.56 \pm 0.40$  D), respectively. Increases in axial length in treated groups versus (vs) washout groups were  $0.17 \pm 0.14$  mm (vs  $0.33 \pm 0.17$  mm),  $0.20 \pm 0.15$  mm (vs  $0.29 \pm 0.14$  mm) and  $0.24 \pm 0.18$  mm (vs  $0.29 \pm 0.15$  mm) for the 0.05%, 0.025%, and 0.01% concentrations, respectively (Table 2). In a one-year randomized clinical trial including Chinese children (n=220) 0.01% atropine eye drops slowed myopia progression, but the study was limited by an approximately 70% follow-up.<sup>23</sup> In the Atropine for the Treatment of Childhood Myopia in India (I-ATOM) including 100 Indian children, 0.01% atropine showed a significant reduction of spherical equivalent progression, but the changes in AL were not statistically significant.<sup>24</sup> In a 2-year randomized controlled trial including Japanese children (n=168) 0.01% atropine drops reduced myopia progression.<sup>25</sup> However, the reduction in myopia progression was only observed at the end of 2 years of treatment (a reduction of 0.22 D for spherical equivalent and 0.14 mm for AL compared with the placebo eye drops) and the effect was moderate. In another 1-year randomized controlled trial including Chinese children (n=400), 0.02% and 0.01% atropine drops reduced myopia progression, but the effect was concentration depended.<sup>26</sup> Pupil diameter, accommodative amplitude and symptoms were similar between the two concentrations. In a recent real-world study (n=183 children), although 0.01% atropine eye drops slowed axial length progression (0.08 mm), the effect was of minor clinical

importance.<sup>27</sup> However, the use of 0.05% topical atropine in young White children with progressive myopia may lead to more side effects compared to 0.01%, which can compromise parent's acceptance or children's compliance.<sup>28</sup> The results from the published evidence on Asian populations demonstrate that 0.01% atropine seems to be less effective in the treatment of myopia progression. A new ongoing randomized controlled trial, The Myopia Outcome Study of Atropine in Children (MOSAIC), may elucidate the results of efficacy of 0.01% atropine for myopia control in a western European population.<sup>29</sup>

The efficacy and safety of eight atropine concentrations for myopia control in children was reported in a network meta-analysis.<sup>30</sup> The most beneficial atropine concentration for control of overall myopia progression was the 0.05%. Based on published studies and current knowledge it seems that the atropine dose (aggressiveness of therapy) should be adjusted based on the risk factors and progression; the use of minimal concentration is advised (maximize the treatment effect with minimum side effects). Although many studies have been published about efficacy and safety of atropine there are key questions that have not been addressed, such as when to start atropine treatment and to what age should it be continued. Other questions remain unanswered such as frequency and time of application and tapering schedule. Nevertheless, the 3-year LAMP study results showed the benefits of continued low-dose atropine treatment for all concentrations for all three years compared with a washout regimen.<sup>22</sup> The rebound was clinically small for the three atropine concentrations and was least for older children. Thus, continuing treatment may be advisable for younger children.

## Orthokeratology

Orthokeratology lenses are rigid oxygen-permeable contact lens with a reverse-geometry-design that are worn overnight. The lenses reshape the cornea temporarily to correct refractive error and provide the advantage of clear vision during the day without the need for optical correction (Table 1). The basic mechanism of orthokeratology lenses is to change refraction reducing myopia by mechanically flattening the cornea and at the same time shortening of axial length.

The effectiveness and safety of orthokeratology lenses have been tested in numerous studies. The results of one of the first randomized clinical trials were reported in the 1980s with the Berkeley Orthokeratology Study.<sup>31-33</sup> In this randomized controlled trial, the authors compared myopia progression with orthokeratology lenses to a control group wearing conventional rigid contact lenses and concluded that it was possible to reduce myopia by about 1D, but the results were not permanent and quality of vision was unstable during non-wear periods. Since then, several studies were conducted and the long term effectiveness of orthokeratology lenses for myopia control has been shown in a twelve-year retrospective cohort study in Taiwan.<sup>34</sup> In recent studies, Orthokeratology lenses have been shown to reduce AL elongation in Caucasian (randomized controlled trials) and Asian (study with retrospective design) children (Table 2).<sup>35-37</sup> In a 1.5-year randomized controlled trial the average elongation in the orthokeratology group was 0.24 mm smaller than the control group in Danish Children.<sup>37</sup> In this randomized controlled trial there were no fast myopia progressors in the orthokeratology group and no vision-threatening adverse events were reported. In a 2-year retrospective study orthokeratology lenses reduced myopia progression by 0.85 D and axial length by 0.19 mm in Japanese children.<sup>35</sup> In another 2-year retrospective study orthokeratology lenses reduced axial length progression by 0.50 mm in

Chinese children.<sup>36</sup> The axial length growth was significantly reduced in bilateral myopic anisometropia with greater effects in the more myopic eye (difference of .07 mm).

The major concern with orthokeratology treatment is safety, but no severe events have been reported in a recent meta-analysis.<sup>38</sup> The incidence of microbial keratitis in children wearing orthokeratology lenses is low and with similar rates as daily wear soft contact lenses.<sup>39</sup> Nevertheless, it is advisable to monitor corneal staining and mild corneal epithelial disorders which are common findings, and it is important to prevent more serious corneal surface diseases that may lead to visual impairment.<sup>37,40-42</sup> Orthokeratology lenses are widely used and studied but the dropout rates are usually high, and the number of subjects included is low. Also, the complications and causes of drop out are usually not well explained.

### **Contact Lenses with Novel Technology and Designs**

Contact lenses with novel technology and designs are emerging treatments (Table 1) to control myopia progression.<sup>43</sup> MiSight (CooperVision, Inc., Pleasanton, CA) soft contact lenses present a dual-focus optical design that provides myopic defocus.<sup>44</sup> The lens comprises a central zone with the distance correction and concentric peripheral zones with additional positive power. In a 3-year randomized controlled trial MiSight lenses slowed spherical equivalent progression by 0.73 D ( $-0.51 \pm 0.64$  compared with  $-1.24 \pm 0.61$  D in the control group) and axial length elongation by 0.32 mm ( $0.30 \pm 0.27$  D compared with  $0.62 \pm 0.30$  mm in the controls; Table 2). In this study only 75.5% of the children completed the study (53 MiSight children and 56 controls).<sup>44</sup> The results of the seven-year study showed that the myopia control gains with

MiSight lenses were retained for the first 12 months following treatment cessation (Chamberlain P, et al. OVS 2021;98:E-abstract 215130).

In another 3-year randomized controlled trial Walline *et al.* reported slower myopia progression and axial elongation with Biofinity multifocal soft contact lenses (Cooper Vision) with a +2.50 add power (treated versus control: -0.56 D vs. -1.01 D and 0.39 mm versus 0.62 mm).<sup>45</sup>

A randomized controlled trial was conducted using silicone hydrogel contact lenses with four different designs.<sup>46</sup> The design with extended depth of focus that incorporated higher order aberrations to modulate retinal image quality (up to +1.75D or +2.50D) provided the best performance. The results showed significant reductions in spherical equivalent progression and axial length elongation for the extended depth of focus design lenses in the treated groups compared with controls (spherical equivalent progression reduced by 0.27 to 0.37 D; axial length elongation reduced by 0.41 to 0.46 mm).

### **Multifocal and other Design Spectacle Lenses**

Multifocal spectacles such as bifocal or progressive addition lenses have been tested in the treatment of myopia progression. In the past few years, lenses with novel designs have emerged (Table 1). Defocus incorporated multiple segments (DIMS) spectacles lenses (now marketed as Hoya MiYOSMART) are based on simultaneous defocus, providing peripheral myopic defocus.<sup>47</sup> The lenses consist of a central optical zone that corrects distance refractive error and numerous small circular segments of +3.50D distributed in the mid-peripheral area. The results of a 2-year randomized controlled trial plus a 1-year follow-up study without randomization

showed that the overall 3 years control effect was a reduction of myopia by 0.71 and axial length decrease by 0.37 mm (Table 2).<sup>47,48</sup> Highly aspherical lenses (Essilor Stellest) are aspherical lenses that deviate rays of light continuously in a non-linear manner, creating a three-dimensional quantity of light in front of the retina, defined as the volume of myopic defocus.<sup>49</sup> The results of the 2-year randomized controlled trial showed that highly aspherical lenslet lenses reduced myopia progression by 0.80 D and slowed axial length by 0.35 mm compared with the control group (Table 2) with better results for children wearing the lenses for at least 12 hours per day.<sup>50</sup> The Correction of Myopia Evaluation Trial (COMET) showed that progressive addition lenses (PALs) slowed myopia by 0.28 D over three years, whereas defocus incorporated multiple segments and highly aspherical lenslet lenses slowed myopia by 0.71 D and 0.80 D over three and two years, respectively.<sup>51,52</sup> Vision Diffusion Optics Technology (DOT) lenses from SightGlass Vision reduce contrast signaling in the retina. The results of the 2-year randomized controlled trial NCYPRESS clinical study (n=256 aged 6 to 10 years old) showed that children who wore two different designs of diffusion optics technology lenses had a reduction in myopia progression by 0.52 D, and a reduction in axial length progression by 0.21 mm compared with the control group (Rappon J, et al. IOVS 2022;63: ARVO E-Abstract 408).

### **Treatment Combinations**

Randomized controlled trials showed that axial length elongation was lower in the combination group where 0.01% topical atropine and OK therapies were implemented compared with orthokeratology only or atropine only groups (Table 2). The results of a 1-year randomized controlled trial showed that Chinese children treated with a combination of orthokeratology and 0.01% atropine had better spherical equivalent (mean difference = 0.18 D) and axial length

(mean difference=0.14 mm) control compared with children that only wore orthokeratology lenses.<sup>53,54</sup> In another 1-year randomized controlled trials axial length was significantly slowed by 0.09 mm with a treatment combination of orthokeratology and 0.01% atropine compared with orthokeratology alone.<sup>55</sup> Comparable results were found by Kinoshita *et al.*, with a reduction of 0.11 mm in children using the combination therapy (orthokeratology and 0.01% atropine) compared with orthokeratology.<sup>56</sup> Nevertheless, treatment combination therapy may be more effective in children with low baseline myopia due to pupil enlargement and enhanced optical effect of orthokeratology.<sup>56</sup> Fast myopia progressors and poor responders to orthokeratology may not respond well to combination therapy with 0.01% nightly atropine, and AL elongation was similar to orthokeratology monotherapy.<sup>57</sup> The additive effect of treatment combinations is promising, but the effect seems stronger in the first six months of treatment, some children are non-responders, and more research is necessary to study if the additive effect is long-lasting. However, it seems that not all treatment combinations are effective. For example, the Bifocal & Atropine in Myopia (BAM) study (3-year randomized controlled trial) results showed that the effect of combining 0.01% atropine with a soft multifocal contact lenses with a +2.50 D add power failed to demonstrate better myopia control than soft multifocal contact lenses alone.<sup>58</sup> Thus, several questions remain regarding combining 0.01% atropine with other treatments options and further research is necessary to understand which treatment combinations are effective.

### **Time Spent Outdoors**

Based on population-based and interventional studies, the IMI Prevention of Myopia and Its Progression paper, recommended schoolchildren to spend more time outdoors to reduce the incidence of myopia.<sup>19</sup> This is a safe and non-invasive strategy that can also be used to promote

healthier lifestyles for children. Spending time outdoors has been shown to slow the change in axial elongation in a meta-analysis (pooled mean difference of outdoor group compared with control of  $-0.03$  (95% CI  $-0.03$  to  $-0.03$ ) mm) reducing the risk of myopia development.<sup>59</sup> It has been recommended that a child should spend 2 hours outdoors every day.<sup>60-62</sup>

The evidence for the effect of time outdoors on myopia progression remains mixed, which may indicate a small effect or an effect of limited clinical significance. Guo et al. conducted a prospective interventional study implementing a school outdoor program (30 minutes every day for 1 year) and showed that the effect of extended outdoor time on the reduction of myopic progression was mainly observed in non-myopic children.<sup>63</sup> This is an opportunity for myopic control in need of further study.

### **Prognosis and other Treatment Considerations**

Compliance with treatment seems to be an important factor. As such, expectations for treatment should be discussed with parents before starting treatment and careful planning is necessary to individualize the approach.

There are many unanswered questions which will have significant impact on clinical prognosis. The loss of treatment benefit over time is a similar feature of all myopia-control randomized controlled trials, with most of the effect happening in the first year of treatment. Nevertheless, the effect has typically been clinically meaningful. There is no valid progression-based criterion for initiation of myopia control and age at onset remains as one of the most important factors in predicting myopia progression.<sup>64</sup> Other risks factors influence progression, such as ethnicity, sex,

and parental myopia.<sup>65</sup> Younger age was associated with poor treatment response with younger children requiring 0.05% concentration (compared with 0.025% and 0.01%) to achieve similar reduction in myopic progression as older children receiving lower concentrations.<sup>66</sup> Thus, one approach might be to start with higher atropine concentrations in younger children and possibly switch later to lower doses. Although myopia progression diminishes with age, there are reports of myopia progression and axial elongation in adults with high myopia.<sup>1,12,67</sup> Furthermore, not all children respond to treatment<sup>27</sup> with some non-responders showing myopia progression even into early adulthood.

It is not known yet if there is value in treating pre-myopes ( $SE \leq +0.75$  D and  $> -0.50$  D) where a combination of baseline refraction, age, and other quantifiable risk factors suggest likely development of myopia.<sup>68</sup> However, a spherical equivalent refraction  $<+0.75$  D at age 8 years was predictive of the onset of juvenile myopia (AUC=0.88) and baseline spherical equivalent seems to be the best single predictor of onset of myopia (AUC=0.87 to 0.93).<sup>69,70</sup> The results of the addition of environmental and genetic factors to baseline spherical equivalent to improve the prediction of myopia have been mixed. In the Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study, baseline SE at age of 6 years and number of myopic parents improved the prediction of myopia onset, but the sensitivity of these factors was low.<sup>71</sup> Similarly, in the Singapore Cohort Of the Risk factors for Myopia (SCORM) the addition of other factors including sex, race, school, books per week and parental myopia only marginally improved the prediction of high myopia.<sup>72</sup>

The use of percentile growth curves in clinical practice to monitor myopia progression has been proposed in a previous study and baseline spherical equivalent measures (5<sup>th</sup> percentile) provided the best identification of children with increased risk of developing high myopia in adulthood.<sup>73</sup> In another study increased axial length above the first quartile was predictive of high myopia (Spherical equivalent  $\leq$  -5.00D) in adolescent years.<sup>74</sup> Using data from the Generation R study, The Avon Longitudinal Study of Parents and Children and The Rotterdam Study III, the authors developed European axial length charts to determine to estimate the risk of developing high myopia.<sup>75</sup> There are a few online myopia calculators that help practitioners understand myopia and axial length progression over time. Those are based on progression curves generated from annual Spherical equivalent progression data and allow the clinician to enter patient measurements and to visualize likely myopia progression for each child.

Machine learning algorithms, have been validated using a large real-world dataset to predict high myopia by 18 years with clinically acceptable accuracy among Chinese school-aged populations.<sup>76</sup> Studies using deep learning analytics have shown that is possible to predict refractive error from retinal fundus imaging.<sup>77</sup> In a systematic review the authors concluded that age-specific spherical equivalent is the strongest predictor of myopia, while the additive effect of data including lifestyle, genetic and imaging data was inconclusive.<sup>78</sup> Future improvement of myopia progression prediction models for use in routine clinical practice may require the development of websites, phone applications and other accessible tools.<sup>79</sup>

## CONCLUSIONS

Management of myopia progression includes treatment with topical atropine, orthokeratology lenses, multifocal contact lenses, and spectacles with novel technology and designs. The optimal approach depends on treatment availability, parent's acceptance, and specific patient clinical features such as age, baseline myopia or lifestyle. Topical atropine and orthokeratology lenses are treatments with proven effectiveness, although there are side effects with higher atropine concentrations or risk of microbial keratitis with orthokeratology lenses. The effect of atropine in prevention of myopic progression has been known for over hundred years and numerous studies have been conducted. Nonetheless, further studies are necessary to inform on best doses and which dosages have least side effects. Contact lenses with novel design spectacle lenses are emerging treatments. These new myopia control treatments may be helpful, and the benefit seems greater than what has been found with 0.01 % atropine. However, more data from different races and ethnicities are needed to fully understand the effect of concentration. Rebound is an important consideration, although it has been small in older children based on the results of LAMP study and the MiSight study. More research is necessary on following up children who discontinued treatment modalities such as the defocus incorporated multiple segments or diffusion optics technology to determine rebound effects. Follow-up rates are mostly in children, and it is difficult to predict if treatment effects will persist with longer follow-up. Given the documented progression of myopia in many children, a long-term treatment approach in childhood and adolescence is necessary. It is also not clear whether the available myopia control treatments will be sufficiently powerful to prevent the development of pathologic myopia and its vision-threatening features in enough patients to warrant these interventions.

## REFERENCES

1. Sankaridurg P, Tahhan N, Kandel H, et al. IMI Impact of Myopia. *Invest Ophthalmol Vis Sci* 2021;62:2.
2. Haarman AG, Enthoven CA, Tideman JL, Tedja MS, et al. The Complications of Myopia: A Review and Meta-Analysis. *Invest Ophthalmol Vis Sci* 2020;61:49.
3. Ohno-Matsui K, Wu PC, Yamashiro K, et al. IMI Pathologic Myopia. *Invest Ophthalmol Vis Sci* 2021;62:5.
4. Bullimore MA, Ritchey ER, Shah S, et al. The Risks and Benefits of Myopia Control. *Ophthalmology* 2021; 128:1561-79.
5. Pärssinen O, Kauppinen M. Associations of Near Work Time, Watching TV, Outdoors Time, and Parents' Myopia with Myopia among School Children Based on 38-year-old Historical Data. *Acta Ophthalmol* 2021;100:e430-8.
6. Bez D, Megreli J, Bez M, et al. Association between Type of Educational System and Prevalence and Severity of Myopia among Male Adolescents in Israel. *JAMA Ophthalmol* 2019;137:887-93.
7. Zadnik K, Mutti DO. Outdoor Activity Protects Against Childhood Myopia—Let the Sun Shine In. *JAMA Pediatr* 2019;173:415-6.
8. Rozema JJ, Boulet C, Cohen Y, et al. Reappraisal of the Historical Myopia Epidemic in Native Arctic Communities. *Ophthalmic Physiol Opt* 2021;41:1332-45.
9. Zhang X, Cheung SL, Chan HN, et al. Myopia Incidence and Lifestyle Changes among School Children during the COVID-19 Pandemic: A Population-based Prospective Study. *Br J Ophthalmol* 2021;10.1136/bjophthalmol-2021-319307.

10. Mirhajianmoghadam H, Piña A, Ostrin LA. Objective and Subjective Behavioral Measures in Myopic and Non-Myopic Children During the COVID-19 Pandemic. *Transl Vis Sci Technol* 2021;10:4.
11. Hu Y, Ding X, Guo X, et al. Association of Age at Myopia Onset with Risk of High Myopia in Adulthood in a 12-year Follow-Up of a Chinese Cohort. *JAMA Ophthalmol* 2020;138:1129-34.
12. Polling JR, Klaver C, Tideman JW. Myopia Progression from Wearing First Glasses to Adult Age: The DREAM Study. *Br J Ophthalmol* 2022;106:820-4.
13. Walline JJ, Lindsley K, Vedula SS, et al. Interventions to slow progression of myopia in children. *Cochrane Database Syst Rev* December 2011;7:CD004916.
14. Leo SW, Young TL. An Evidence-based Update on Myopia and Interventions to Retard its Progression. *J AAPOS* 2011;15:181-9.
15. Saw SM, Shih-Yen EC, Koh A, Tan D. Interventions to Retard Myopia Progression in Children. *Ophthalmology* 2002;109:415-21.
16. Huang J, Wen D, Wang Q, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children. *Ophthalmology* 2016;123:697-708.
17. Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the Effect of Atropine and Cyclopentolate on Myopia. *Ann Ophthalmol* 1989;21:180-2, 187.
18. Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2. *Ophthalmology* 2016;123:391-9.
19. Jonas JB, Ang M, Cho P, et al. IMI Prevention of Myopia and Its Progression. *Invest Ophthalmol Vis Sci* 2021;62:6.

20. Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study. *Ophthalmology* 2019;126:113-24.
21. Yam JC, Li FF, Zhang X, et al. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study. *Ophthalmology* 2020;127:910-9.
22. Yam JC, Zhang XJ, Zhang Y, et al. Three-year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued versus Washout. Phase 3 Report. *Ophthalmology* 2022; 129:308-21.
23. Wei S, Li SM, An W, et al. Safety and Efficacy of Low-dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children. *JAMA Ophthalmol* 2020;138:1178-84.
24. Saxena R, Dhiman R, Gupta V, et al. Atropine for the Treatment of Childhood Myopia in India: Multicentric Randomized Trial. *Ophthalmology* 2021;128:1367-9.
25. Hieda O, Hiraoka T, Fujikado T, et al. Efficacy and Safety of 0.01% Atropine for Prevention of Childhood Myopia in a 2-year Randomized Placebo-controlled Study. *Jpn J Ophthalmol* 2021;65:315-25.
26. Fu A, Stapleton F, Wei L, et al. Effect of Low-dose Atropine on Myopia Progression, Pupil Diameter and Accommodative Amplitude: Low-dose Atropine and Myopia Progression. *Br J Ophthalmol* 2020;104:1535-41.
27. Kaymak H, Graff B, Schaeffel F, et al. A Retrospective Analysis of the Therapeutic Effects of 0.01% Atropine on Axial Length Growth in Children in a Real-life Clinical Setting. *Graefe's Arch Clin Exp Ophthalmol* 2021;259:3038-92.
28. Joachimsen L, Farassat N, Bleul T, et al. Side Effects of Topical Atropine 0.05% Compared to 0.01% for Myopia Control in German School Children: A Pilot Study. *Int Ophthalmol* 2021;41:2001-8.

29. McCrann S, Flitcroft I, Strang NC, et al. Myopia Outcome Study of Atropine in Children (MOSAIC): An Investigator-led, Double-masked, Placebo-controlled, Randomised Clinical Trial Protocol. *HRB Open Res* 2019;2:15.
30. Ha A, Kim SJ, Shim SR, et al. Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis. *Ophthalmology* 2022;129:322-33.
31. Brand RJ, Polse KA, Schwalbe JS. The Berkeley Orthokeratology Study, Part I: General Conduct of the Study. *Am J Optom Physiol Opt* 1983;60:175-86.
32. Polse KA, Brand RJ, Schwalbe JS, et al. The Berkeley Orthokeratology Study, Part II: Efficacy and Duration. *Am J Optom Physiol Opt* 1983;60:187-98.
33. Polse KA, Brand RJ, Keener RJ, et al. The Berkeley Orthokeratology Study, Part III: safety. *Am J Optom Physiol Opt* 1983;60:321-8.
34. Lee YC, Wang JH, Chiu CJ. Effect of Orthokeratology on Myopia Progression: Twelve-year Results of a Retrospective Cohort Study. *BMC Ophthalmol* 2017;17:243.
35. Nakamura Y, Hieda O, Yokota I, et al. Comparison of Myopia Progression between Children Wearing Three Types of Orthokeratology Lenses and Children Wearing Single-vision Spectacles. *Jpn J Ophthalmol* 2021;65:632-43.
36. Xu J, Gao B, Tian Q, et al. Effects of Orthokeratology on Axial Length Elongation in Anisometropes. *Ophthalmic Res* 2021;64:991-1001.
37. Jakobsen TM, Møller F. Control of Myopia Using Orthokeratology Lenses in Scandinavian Children Aged 6 to 12 years. Eighteen-month Data from the Danish Randomized Study: Clinical study Of Near-sightedness; Treatment with Orthokeratology Lenses (CONTROL study). *Acta Ophthalmol* 2022;100:175-82.

38. Walline JJ, Lindsley KB, Vedula SS, et al. Interventions to Slow Progression of Myopia in Children. *Cochrane Database Syst Rev* 2020;1:CD004916.
39. Bullimore MA, Mirsayafov DS, Khurai AR, et al. Pediatric Microbial Keratitis with Overnight Orthokeratology in Russia. *Eye Contact Lens Sci Clin Pract* 2021;47:420-5.
40. Goto T, Shiraishi A, Ohashi Y, et al. A Multicenter Clinical Trial of Orthokeratology in School-aged Children and Adolescents in Japan. *Jpn J Ophthalmol* 2021;65:624-31.
41. Walline JJ, Robboy MW, Hilmantel G, et al. Food and Drug Administration, American Academy of Ophthalmology, American Academy of Optometry, American Association for Pediatric Ophthalmology and Strabismus, American Optometric Association, American Society of Cataract and Refractive Surgery, and Contact Lens Association of Ophthalmologists Co-Sponsored Workshop: Controlling the Progression of Myopia: Contact Lenses and Future Medical Devices. *Eye Contact Lens* 2018;44:205-11.
42. Gispets J, Yébane P, Lupón N, Cardona G, et al. Efficacy, Predictability and Safety of Long-term Orthokeratology: An 18-year Follow-up Study. *Contact Lens Anterior Eye* 2022;45:101530.
43. Prousalis E, Haidich AB, Fontalis A, Ziakas N, et al. Efficacy and Safety of Interventions to Control Myopia Progression in Children: An Overview of Systematic Reviews and Meta-analyses. *BMC Ophthalmol* 2019;19:106.
44. Chamberlain P, Peixoto-de-Matos SC, Logan NS, et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. *Optom Vis Sci* 2019;96:556-67.
45. Walline JJ, Walker MK, Mutti DO, et al. Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children. *JAMA* 2020;324:571-80.

46. Sankaridurg P, Bakaraju RC, Naduvilath T, et al. Myopia Control with Novel Central and Peripheral Plus Contact Lenses and Extended Depth of Focus Contact Lenses: 2 Year Results from a Randomised Clinical Trial. *Ophthalmic Physiol Opt* 2019;39:294-307.
47. Lam CS, Tang WC, Lee PH, et al. Myopia Control Effect of Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens in Chinese Children: Results of a 3-year Follow-up Study. *Br J Ophthalmol* 2021;10.1136/bjophthalmol-2020-317664.
48. Lam CS, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses Slow Myopia Progression: A 2-year Randomised Clinical Trial. *Br J Ophthalmol* 2020;104:363–8.
49. Bao J, Yang A, Huang Y, Li X, et al. One-year Myopia Control Efficacy of Spectacle Lenses with Aspherical Lenslets. *Br J Ophthalmol* 2021;doi:10.1136/bjophthalmol-2020-318367.
50. Bao J, Huang Y, Li X, et al. Spectacle Lenses with Aspherical Lenslets for Myopia Control vs. Single-Vision Spectacle Lenses. *JAMA Ophthalmol* 2022;140:472-8.
51. Gwiazda J, Hyman L, Hussein M, et al. A Randomized Clinical Trial of Progressive Addition Lenses versus Single-vision Lenses on the Progression of Myopia in Children. *Invest Ophthalmol Vis Sci* 2003;44:1492-500.
52. Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group. Progressive-addition Lenses versus Single-vision Lenses for Slowing Progression of Myopia in Children with High Accommodative Lag and Near Esophoria. *Invest Ophthalmol Vis Sci* 2011;52:2749-57.
53. Hao Q, Zhao Q. Changes in Subfoveal Choroidal Thickness in Myopic Children with 0.01% Atropine, Orthokeratology, or their Combination. *Int Ophthalmol* 2021;41:2963-71.

54. Zhao Q, Hao Q. Clinical Efficacy of 0.01% Atropine in Retarding the Progression of Myopia in Children. *Int Ophthalmol* 2021;41:1011-7.
55. Tan Q, Ng AL, Choy BN, et al. One-year Results of 0.01% Atropine with Orthokeratology (AOK) Study: A Randomised Clinical Trial. *Ophthalmic Physiol Opt* 2020;40:557-66.
56. Kinoshita N, Konno Y, Hamada N, et al. Efficacy of Combined Orthokeratology and 0.01% Atropine Solution for Slowing Axial Elongation in Children with Myopia: A 2-year Randomised Trial. *Sci Rep* 2020;10:12750.
57. Chen Z, Zhou J, Xue F, et al. Two-year Add-on Effect of Using Low Concentration Atropine in Poor Responders of Orthokeratology in Myopic Children. *Br J Ophthalmol* March 2021;10.1136/bjophthalmol-2020-317980.
58. Jones JH, Mutti DO, Jones-Jordan LA, Walline JJ. Effect of Combining 0.01% Atropine with Soft Multifocal Contact Lenses on Myopia Progression in Children. *Optom Vis Sci* 2022;99:434-42.
59. Cao K, Wan Y, Yusufu M, Wang N. Significance of Outdoor Time for Myopia Prevention: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials. *Ophthalmic Res* 2020;63:97-105.
60. Klaver CW, Polling JR, Enthoven CA. 2020 as the Year of Quarantine Myopia. *JAMA Ophthalmol* 2021;139:300-1.
61. Modjtahedi BS, Abbott RL, Fong DS, et al. Reducing the Global Burden of Myopia by Delaying the Onset of Myopia and Reducing Myopic Progression in Children. *Ophthalmology* 2021;128:816-26.

62. Wu PC, Chen CT, Chang LC, et al. Increased Time Outdoors Is Followed by Reversal of the Long-Term Trend to Reduced Visual Acuity in Taiwan Primary School Students. *Ophthalmology* 2020;127:1462-9.
63. Guo Y, Liu L, Lv Y, et al. Outdoor Jogging and Myopia Progression in School Children From Rural Beijing: The Beijing Children Eye Study. *Transl Vis Sci Technol* 2019;8:2.
64. Bullimore MA, Richdale K. Myopia Control 2020: Where Are We and Where Are We Heading? *Ophthalmic Physiol Opt* 2020;40:254-70.
65. Jiang X, Tarczy-Hornoch K, Cotter SA, et al. Association of Parental Myopia with Higher Risk of Myopia among Multiethnic Children Before School Age. *JAMA Ophthalmol* 2020;138:501-9.
66. Li FF, Zhang Y, Zhang X, et al. Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine. *Ophthalmology* 2021;128:1180-7.
67. Du R, Xie S, Igarashi-Yokoi T, et al. Continued Increase of Axial Length and Its Risk Factors in Adults With High Myopia. *JAMA Ophthalmol* 2021; 139:1096-103.
68. Jong M, Jonas JB, Wolffsohn JS, et al. IMI 2021 Yearly Digest. *Invest Ophthalmol Vis Sci* 2021;62:7.
69. Zadnik K, Mutti DO, Friedman NE, et al. Ocular Predictors of the Onset of Juvenile Myopia. *Invest Ophthalmol Vis Sci* 1999;40:1936-43.
70. Zadnik K, Sinnott LT, Cotter SA, et al. Prediction of Juvenile-Onset Myopia. *JAMA Ophthalmol* 2015;133:683-9.
71. Jones-Jordan LA, Sinnott LT, Manny RE, et al. Early Childhood Refractive Error and Parental History of Myopia as Predictors of Myopia. *Invest Ophthalmol Vis Sci* 2010;51:115-21.

72. Chua SL, Sabanayagam C, Cheung YB, et al. Age of Onset of Myopia Predicts Risk of High Myopia in Later Childhood in Myopic Singapore Children. *Ophthalmic Physiol Opt* 2016;36:388–94.
73. Chen Y, Zhang J, Morgan IG, He M. Identifying Children at Risk of High Myopia Using Population Centile Curves of Refraction. *PLoS One* 2016;11:e0167642.
74. Sanz Diez P, Yang LH, Lu MX, et al. Growth Curves of Myopia-related Parameters to Clinically Monitor the Refractive Development in Chinese Schoolchildren. *Graefe's Arch Clin Exp Ophthalmol* 2019;257:1045-53.
75. Tideman JL, Polling JR, Vingerling JR, Jaddoe VV, et al. Axial length growth and the risk of developing myopia in European children. *Acta Ophthalmol* 2018;96:301–9.
76. Lin H, Long E, Ding X, et al. Prediction of Myopia Development among Chinese School-aged Children Using Refraction Data from Electronic Medical Records: A Retrospective, Multicentre Machine Learning Study. *PLOS Med* 2018;15:e1002674.
77. Varadarajan AV, Poplin R, Blumer K, et al. Deep Learning for Predicting Refractive Error From Retinal Fundus Images. *Invest Ophthalmol Vis Sci* 2018;59:2861.
78. Han X, Liu C, Chen Y, He M. Myopia Prediction: A Systematic Review. *Eye* 2022;36:921-9.
79. Chen YX, Tan Z, He MG. Who Needs Myopia Control? *Int J Ophthalmol* 2021;14:1297-301.

**Table 1.** Major Therapies Available for Treatment of Myopia Progression

Modality	Advantages and disadvantages	Mechanism of Action	Other Considerations
<b>Topical atropine</b> eye drops (1.0%, 0.5%, 0.1%, 0.05%, and 0.01%)	<p>Reduces myopia progression and axial elongation in children in a dose-related manner, but a rebound phenomenon occurs with higher doses.</p> <p>The effectiveness and safety were tested in numerous studies over a period of 30 years.</p>	<p>Non-selective muscarinic acetylcholine receptor antagonist.</p> <p>The underlying mechanisms by which it controls myopia progression remain unclear.</p> <p>May influence retinal regulation and scleral muscarinic receptors leading to changes in the scleral matrix to reduce axial elongation.</p>	<p>Higher doses cause pupil dilation and increased sensitivity to light, loss of accommodation and near vision, itching and discomfort. Allergic reaction is possible. Children using higher doses may need photochromic glasses (which darken on exposure to sunlight) if they experience photophobia or if their parents are worried about excessive light exposure. Progressive glasses (reading add) may be prescribed for children with near vision difficulties.</p> <p>Low concentrations are well-tolerated, and they are not associated with photophobia or reading problems.</p>
<b>Orthokeratology</b> contact lenses	<p>Most orthokeratology lenses are worn at night and then removed during the day.</p> <p>The effectiveness and safety were tested in numerous studies over a period of 30 years.</p> <p>The effectiveness was shown in a twelve-year retrospective cohort study in Taiwan.<sup>34</sup></p>	<p>Corneal gas-permeable contact lenses that are designed to flatten the central cornea, leading to midperipheral steeping and peripheral myopic defocus.</p> <p>The exact mechanism underlying the myopia control effect remains unclear. However, animal, and human studies support the theory of peripheral myopic defocus on the retina due to the inverted pattern of corneal peripheral refraction.</p>	<p>Some children report discomfort with lens wear.</p> <p>Risk of complications (e.g., microbial keratitis) is low.</p> <p>Corneal staining is a common finding, and it is recommended to evaluate corneal surface health regularly.</p>
<b>Multifocal soft contact lenses</b>	<p>Are worn during the day.</p> <p>Efficacy is related with compliance (better results for lens wear compliance of at least 6 days per week).</p> <p>The effectiveness was shown in a three-year clinical trial.<sup>44</sup></p>	<p>Provide myopic defocus of light in the periphery while allowing clear vision by focusing light on the central retina. The myopic defocus (light focused in front of the retina) may act as a signal to slow eye growth and reduce myopia progression.</p> <p>Dual focus contact lenses are based on simultaneous defocus providing peripheral myopic defocus and center distance contact lenses are based on peripheral defocus. EDOF lenses provide global retinal image quality optimized for points at and anterior to retina. Points posterior to the retina are deliberately degraded.</p>	<p>Some children report discomfort with lens wear.</p> <p>Risk of complications (e.g., giant papillary conjunctivitis, infiltrative keratitis, ocular allergies, etc.) is low.</p>
<b>Multifocal and other design spectacles</b> (bifocal or progressive addition lenses)	<p>Non-pharmacological option that is well tolerated by children and parents. There are only a few studies on DIMS and HAL lenses and knowledge is based on short-term observations. PALs are not as effective as DIMS or HALT lenses.</p>	<p>DIMS are based on simultaneous defocus, providing peripheral myopic defocus. HAL spectacle lenses are based on volume of myopic defocus, providing peripheral myopic defocus.</p>	<p>Mid-peripheral blurred vision may occur.</p> <p>Rebound phenomenon is not known.</p>

EDOF = extended depth of focus; DIMS = defocus incorporated multiple segments; HAL = highly aspherical lenslets; PALs = progressive addition lenses

**Table 2.** Myopia Progression and Axial Elongation for the Different Treatment Options Available to Control Myopia in Studies Published in 2019-2021.

Study	Modality	Duration and Design	Ethnicity and age range (years)	Reduction in myopia progression in the treatment group vs control at the final follow-up visit	
				SER (D)	AL (mm)
<b>Low-dose atropine</b>					
Yam et al. <sup>20-22</sup>	0.05%, 0.025% and 0.01% atropine	3-year RCT (phase 1, 2 & 3)	Chinese (4 to 12)	0.05%: 0.4 0.025%: 0.22 0.01%: 0.18	0.05%: 0.16 0.025%: 0.09 0.01%: 0.05
Wei et al. <sup>23</sup>	0.01% atropine	1-year RCT	Chinese (mean = 9.64)	0.26	0.09
Saxena et al. <sup>24</sup>		1-year RCT	Indian (6 to 14)	0.19	NS
Hieda et al. <sup>25</sup>		2-year RCT	Japanese (6 to 12)	0.22	0.14
Fu et al. <sup>26</sup>	0.01% and 0.02% atropine	1-year RCT	Chinese (6 to 14)	0.01%: 0.09 0.02% vs 0.01%: 0.04	0.01%: 0.14 0.02% vs 0.01%: 0.04
<b>Orthokeratology (OK)</b>					
Jakobsen & Møller <sup>37</sup>	Four-zone reverse geometry (Dreamlite)	1.5-year RCT	Caucasian (6-12)	---	0.24
Nakamura et al. <sup>35</sup>	Menicon Z Night or ACUVUE Abiliti, αORTHO'K & Emerald™	2-year retrospective	Japanese (mean = 9)	0.85	0.19
Xu et al. <sup>36</sup>	Spherical four-zone (Mengdaiwei, Sino-American joint)	2-year retrospective	Chinese (8-16)	---	0.50
<b>Multifocal Contact Lenses</b>					
Chamberlain et al. <sup>44</sup>	MiSight 1 day	3-year RCT	Caucasian (8-12)	0.73	0.32
Walline et al. <sup>45</sup>	Biofinity +2.50	3-year RCT	Caucasian (7-11)	0.45	0.23
Sankaridurg et al. <sup>46</sup>	Myopic defocus and EDOF (4 designs)	2-year RCT	Chinese (7-13)	0.37 to 0.27	0.41 to 0.46
<b>Multifocal spectacles</b>					
Lam et al. <sup>47,48</sup>	DIMS	2-year RCT + 1-year HC	Chinese (6-12)	0.71	0.37
Bao et al. <sup>49,50</sup>	HAL	2-year RCT	Chinese (8-13)	0.80	0.35
<b>Treatment combinations*</b>					
Hao & Zhao <sup>53,54</sup>	0.01% atropine + OK	1-year RCT	Chinese (8-12)	0.18	0.14
Tan et al. <sup>55</sup>		1-year RCT	Chinese (6-11)	NS	0.09
Kinoshita et al. <sup>56</sup>		2-year RCT	Japanese (8-12)	---	0.11
Huang et al. <sup>58</sup>	0.01% atropine + SMCLs with a +2.50 D add power	3-year RCT	Caucasian & Asian (7-11)	NS	NS

SER, Spherical Equivalent Refraction; AL, Axial Length; SD, Standard Deviation; OK, Orthokeratology; HC, Historical control; EDOF, Extended Depth of Focus DIMS, Defocus incorporated multiple segments; HAL, Highly Aspherical Lenslets; RCT, Randomized Clinical Trial; NS, Differences were not significant; SMCLs, Soft multifocal contact lenses. \*The results of treatment combinations are not relative to controls, but relative to monotherapy.